

## Market Round-up

V8 – 29<sup>th</sup> June, 2018

### General Market News:

- As Ireland signs up to BeNeLuxA, the hope is that we will start to mirror the rates of adoption of innovative medicines that are present in the initiative's other countries.  
<https://www.thepharmaletter.com/article/ireland-going-continental-but-must-fix-pressing-problem-at-home%C2%A0>
- **GSK** is facing “unprecedented” demand for its new shingles vaccine **Shingrix**, suggesting the product could be more successful than the company and analysts initially thought.  
<https://www.reuters.com/article/us-gsk-vaccine-shingles/clamor-for-gsk-shingles-shot-points-to-bigger-profits-idUSKBN1JL191>
- **Amgen** announces new data showing **Repatha** significantly reduced LDL-C & Non-HDL-C in high-risk patients with Type 2 Diabetes  
<https://www.streetinsider.com/Management+Comments/Amgen+%28AMGN%29+Announces+New+Data+Showing+Repatha+%28evolocumab%29+Significantly+Reduced+LDL-C+%26+Non-HDL-C+In+High-risk+Patients+With+Type+2+Diabetes/14337205.html>
- The FDA has placed new bladder cancer limits on **MSD's Keytruda**, **Roche's Tecentriq**  
<https://www.fiercepharma.com/pharma/fda-slaps-new-bladder-cancer-limits-merck-s-keytruda-roche-s-tecentriq>
- U.S. Supreme Court to hear **MSD** appeal over **Fosamax** suits  
<https://www.reuters.com/article/us-usa-court-merck-co/us-supreme-court-to-hear-merck-appeal-over-fosamax-suits-idUSKBN1JO1Y7>
- **AstraZeneca & MSD** pursue wider indication for **Lynparza** on trial success  
[http://www.pharmatimes.com/news/azmsd\\_pursue\\_wider\\_indication\\_for\\_lynparza\\_on\\_trial\\_success\\_1242133](http://www.pharmatimes.com/news/azmsd_pursue_wider_indication_for_lynparza_on_trial_success_1242133)

### Biosimilars/Biologics:

- **Shire** announced results from a retrospective review of more than 2,500 patient records with metastatic adenocarcinoma of the pancreas (mPAC) from nine countries.  
<https://globenewswire.com/news-release/2018/06/22/1528215/0/en/Shire-plc-Large-Scale-European-Review-Suggests-Disparity-in-Symptom-Recognition-and-Standardized-Treatment-for-Metastatic-Adenocarcinoma-of-the-Pancreas.html>
- **Amgen** announces results from Phase 3 study of Biosimilar candidate to **Infliximab**  
<https://www.prnewswire.com/news-releases/amgen-announces-top-line-results-from-phase-3-study-of-abp-710-biosimilar-candidate-to-infliximab-300673019.html>

### Drug Approvals:

- **Gilead** has gained European approval for its new HIV combination therapy **Biktarvy**, hot on the heels of **GSK's** rival **Juluca**.  
[http://www.pmlive.com/pharma\\_news/european\\_commission\\_backs\\_gileads\\_biktarvy\\_1242153](http://www.pmlive.com/pharma_news/european_commission_backs_gileads_biktarvy_1242153)

- The FDA has approved **Shire's Cinryze** for use in young children to treat hereditary angioedema. <https://www.fiercepharma.com/shire-scores-new-fda-thumbs-up-for-hae-med-cinryze-latest-bid-to-fend-off-rival-csl>
- **Pfizer** announced in a press release that the FDA has accepted its new drug application for **Glasdebig** for the treatment of patients with previously untreated acute myeloid leukemia. <https://marketrealist.com/2018/06/pfizers-glasdebig-receives-priority-review-designation>

### **Further Reading:**

- Top 10 Pharmaceutical Companies 2018 – **Oncology**  
<https://www.linkedin.com/pulse/top-10-pharmaceutical-companies-2018-oncology-luca-dezzani-md/>
- **Amgen & Novartis** released findings from a large global patient study regarding **migraines** and their negative impact on work.  
<https://www.prnewswire.com/news-releases/amgen-and-novartis-highlight-findings-from-a-large-global-patient-survey-revealing-that-worldwide-approximately-60-percent-of-employed-people-with-migraine-missed-on-average-a-week-of-work-in-a-month-300673463.html>
- Is Europe Creating a Coalition to Combat Big Pharma?  
<http://www.appliedclinicaltrials.com/europe-creating-coalition-combat-big-pharma>